Author

Björn Magnusson

AstraZeneca (Sweden)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Molecular Biology· 1 Systems Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Assay:CRISPR screen· 1 Organism:mouse· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

Amir Taheri‐GhahfarokhiiD· 1 shared Anders LundiniD· 1 shared Anna BackmarkiD· 1 shared Bastian SchiffthaleriD· 1 shared Benjamin P. Readhead· 1 shared Burcu BestasiD· 1 shared Carly MeadoriD· 1 shared Christine BeckeriD· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMolecular Biology

Amir Taheri‐GhahfarokhiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Molecular BiologyNature CommunicationsPeer-reviewedAug 14, 2023

Simultaneous inhibition of DNA-PK and Pol{Theta} improves integration efficiency and precision of genome editing

Sandra Wimberger, Nina Akrap, Mike A. Firth…·Marcello Maresca

This study identifies AZD7648 and Pol{Theta} inhibitors as a combination (2iHDR) that enhances CRISPR-Cas9 integration efficiency and precision by targeting DNA-PK and MMEJ repair pathways.

137 citationstop 1%

CRISPR screenexperimental assay

𝕏 PostBluesky

Systems BiologybioRxivPreprintJan 4, 2022

Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in In Vitro, In Vivo and Ex Vivo Models of Pulmonary Fibrosis

Farida Ahangari, Christine Becker, Daniel G. Foster…·Gregory Paul Downey

This study identifies saracatinib as a potential anti-fibrotic drug effective in multiple models of pulmonary fibrosis, showing equal or superior efficacy compared to existing treatments.

1 citation

mousebulk RNA-seq

𝕏 PostBluesky